![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 22, 2023 3:39:35 PM
I think management's goal is to help developers provide for a comprehensive cancer treatment line of products derived from state-of-the-art technologies, to include Treg, CAR-T, and Xspray's Hynap technology for CML, to complement our effort with AML. This is already a $2B market for Xspray, and an NDA next year could have added revenue potential, especially if lenz can be effective in enabling nilotinib to cease incurring food interactions, and eliminate the black box warning on their packaging. Lenz could be the "go-to" product for developers bringing these new platforms and therapeutics to market.
https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharmas-xs003-achieves-superior-bioavailability-milestone-matching-tasigna-at-reduced-dosage/
This is frontier cancer cure territory, and lenz will be interwoven into the process.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM